drugset / Trial / NCT04483674
Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of Bictegravir/FTC/TAF in patients with less of 100 days post HIV infection
Timeline
- Start
- 2020-12-04
- Primary completion
- 2022-11
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bictegravir | Small molecule | 50 mg | Oral |
| Subject | emtricitabine | Other / unclassified | 200 mg | Oral |
| Subject | tenofovir alafenamide | Small molecule | 25 mg | Oral |